Fintech

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

Prnewswire·April 20, 2026 at 11:30 AM

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Amazon, Anthropic Deepen AI Partnership
PYMNTS
Commercial Loans Show US Economy Defies Forecasts
PYMNTS
Zenskar Raises $15 Million for Agentic AI
PYMNTS
Apple Hardware Leader John Ternus to Succeed CEO
PYMNTS

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

Amazon, Anthropic Deepen AI Partnership

Commercial Loans Show US Economy Defies Forecasts

Zenskar Raises $15 Million for Agentic AI

Apple Hardware Leader John Ternus to Succeed CEO